Vatera Healthcare Partners

ImmusanT, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing therapies and diagnostics for celiac disease. Founded in 2010, the company aims to restore tolerance to gluten in patients with this autoimmune disorder. Its primary product, Nexvax2, is a therapeutic vaccine designed to treat, prevent, and diagnose celiac disease. Additionally, ImmusanT has developed a functional T-cell test that aids in diagnosing and monitoring the maintenance of immune tolerance in patients undergoing peptide-based therapy. By leveraging advancements in immunology, ImmusanT seeks to enhance the management of celiac disease and potentially other autoimmune conditions.

Melinta Therapeutics, Inc. is a commercial-stage pharmaceutical company specializing in the discovery, development, and commercialization of anti-infective therapies targeting bacterial infections. The company offers several products, including Baxdela, Vabomere, Orbactiv, and Minocin, which address various acute bacterial skin infections and gram-negative infections. Recognizing the urgent need for new antibiotics to combat drug-resistant infections, Melinta is advancing delafloxacin, currently in Phase 3 development for treating acute bacterial skin and skin structure infections. The company also focuses on developing innovative antibiotics aimed at overcoming resistant pathogens associated with serious hospital infections. Established in 2000, Melinta Therapeutics is headquartered in Morristown, New Jersey, and operates with support from strategic partners in the healthcare sector.

ImmusanT, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing therapies and diagnostics for celiac disease. Founded in 2010, the company aims to restore tolerance to gluten in patients with this autoimmune disorder. Its primary product, Nexvax2, is a therapeutic vaccine designed to treat, prevent, and diagnose celiac disease. Additionally, ImmusanT has developed a functional T-cell test that aids in diagnosing and monitoring the maintenance of immune tolerance in patients undergoing peptide-based therapy. By leveraging advancements in immunology, ImmusanT seeks to enhance the management of celiac disease and potentially other autoimmune conditions.

Melinta Therapeutics, Inc. is a commercial-stage pharmaceutical company specializing in the discovery, development, and commercialization of anti-infective therapies targeting bacterial infections. The company offers several products, including Baxdela, Vabomere, Orbactiv, and Minocin, which address various acute bacterial skin infections and gram-negative infections. Recognizing the urgent need for new antibiotics to combat drug-resistant infections, Melinta is advancing delafloxacin, currently in Phase 3 development for treating acute bacterial skin and skin structure infections. The company also focuses on developing innovative antibiotics aimed at overcoming resistant pathogens associated with serious hospital infections. Established in 2000, Melinta Therapeutics is headquartered in Morristown, New Jersey, and operates with support from strategic partners in the healthcare sector.

Pearl Therapeutics is a private company focused on developing dual and triple combination therapies for prevalent respiratory diseases, particularly chronic obstructive pulmonary disease (COPD), asthma, and rhinosinusitis. The company aims to enhance patient care by providing advanced inhaled therapies through familiar metered dose inhalers. Led by an experienced team specializing in respiratory product development, Pearl Therapeutics is dedicated to creating alternatives that improve safety and efficacy compared to existing treatments, ultimately striving for better clinical outcomes for patients and healthcare providers.

Melinta Therapeutics, Inc. is a commercial-stage pharmaceutical company specializing in the discovery, development, and commercialization of anti-infective therapies targeting bacterial infections. The company offers several products, including Baxdela, Vabomere, Orbactiv, and Minocin, which address various acute bacterial skin infections and gram-negative infections. Recognizing the urgent need for new antibiotics to combat drug-resistant infections, Melinta is advancing delafloxacin, currently in Phase 3 development for treating acute bacterial skin and skin structure infections. The company also focuses on developing innovative antibiotics aimed at overcoming resistant pathogens associated with serious hospital infections. Established in 2000, Melinta Therapeutics is headquartered in Morristown, New Jersey, and operates with support from strategic partners in the healthcare sector.

Pearl Therapeutics is a private company focused on developing dual and triple combination therapies for prevalent respiratory diseases, particularly chronic obstructive pulmonary disease (COPD), asthma, and rhinosinusitis. The company aims to enhance patient care by providing advanced inhaled therapies through familiar metered dose inhalers. Led by an experienced team specializing in respiratory product development, Pearl Therapeutics is dedicated to creating alternatives that improve safety and efficacy compared to existing treatments, ultimately striving for better clinical outcomes for patients and healthcare providers.

Pearl Therapeutics is a private company focused on developing dual and triple combination therapies for prevalent respiratory diseases, particularly chronic obstructive pulmonary disease (COPD), asthma, and rhinosinusitis. The company aims to enhance patient care by providing advanced inhaled therapies through familiar metered dose inhalers. Led by an experienced team specializing in respiratory product development, Pearl Therapeutics is dedicated to creating alternatives that improve safety and efficacy compared to existing treatments, ultimately striving for better clinical outcomes for patients and healthcare providers.

ImmusanT, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing therapies and diagnostics for celiac disease. Founded in 2010, the company aims to restore tolerance to gluten in patients with this autoimmune disorder. Its primary product, Nexvax2, is a therapeutic vaccine designed to treat, prevent, and diagnose celiac disease. Additionally, ImmusanT has developed a functional T-cell test that aids in diagnosing and monitoring the maintenance of immune tolerance in patients undergoing peptide-based therapy. By leveraging advancements in immunology, ImmusanT seeks to enhance the management of celiac disease and potentially other autoimmune conditions.

Pearl Therapeutics is a private company focused on developing dual and triple combination therapies for prevalent respiratory diseases, particularly chronic obstructive pulmonary disease (COPD), asthma, and rhinosinusitis. The company aims to enhance patient care by providing advanced inhaled therapies through familiar metered dose inhalers. Led by an experienced team specializing in respiratory product development, Pearl Therapeutics is dedicated to creating alternatives that improve safety and efficacy compared to existing treatments, ultimately striving for better clinical outcomes for patients and healthcare providers.